The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

"Intellia Therapeutics’ stock rocked by patient death in gene therapy trial" was originally created and published by Clinical ...

Intellia Therapeutics has acknowledged the death of the elderly patient hospitalized last week in its Phase III trial of assessing nexiguran ziclumeran (nex-z) in transthyretin amyloidosis with ...

The Cambridge-based biotech company is studying the use of Crispr, the Nobel Prize-winning gene-editing technology, to treat ...

Intellia Therapeutics faced a devastating blow as news emerged of a patient death in a crucial clinical trial, prompting ...

The approach is “very exciting,” but one expert says a lot more research is needed, especially around safety, before clinical ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...